BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 23978351)

  • 1. Phenotypic features of Crohn's disease associated with failure of medical treatment.
    Moran GW; Dubeau MF; Kaplan GG; Yang H; Seow CH; Fedorak RN; Dieleman LA; Barkema HW; Ghosh S; Panaccione R;
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.
    Marehbian J; Arrighi HM; Hass S; Tian H; Sandborn WJ
    Am J Gastroenterol; 2009 Oct; 104(10):2524-33. PubMed ID: 19532125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
    Ong DE; Kamm MA; Hartono JL; Lust M
    J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors of thiopurine-related adverse events in Crohn's disease.
    Moran GW; Dubeau MF; Kaplan GG; Yang H; Eksteen B; Ghosh S; Panaccione R
    World J Gastroenterol; 2015 Jul; 21(25):7795-804. PubMed ID: 26167079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009.
    Lakatos PL; Golovics PA; David G; Pandur T; Erdelyi Z; Horvath A; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Veres G; Lovasz BD; Szathmari M; Kiss LS; Lakatos L
    Am J Gastroenterol; 2012 Apr; 107(4):579-88. PubMed ID: 22233693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
    Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
    Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease.
    Cossu A; Biancone L; Ascolani M; Pallone F; Boirivant M
    J Crohns Colitis; 2013 Jul; 7(6):441-50. PubMed ID: 22840925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study.
    Nørgård B; Pedersen L; Christensen LA; Sørensen HT
    Am J Gastroenterol; 2007 Jul; 102(7):1406-13. PubMed ID: 17437503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
    van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
    Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
    Papay P; Reinisch W; Ho E; Gratzer C; Lissner D; Herkner H; Riss S; Dejaco C; Miehsler W; Vogelsang H; Novacek G
    Am J Gastroenterol; 2010 May; 105(5):1158-64. PubMed ID: 20010925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
    Cosnes J; Bourrier A; Laharie D; Nahon S; Bouhnik Y; Carbonnel F; Allez M; Dupas JL; Reimund JM; Savoye G; Jouet P; Moreau J; Mary JY; Colombel JF;
    Gastroenterology; 2013 Oct; 145(4):758-65.e2; quiz e14-5. PubMed ID: 23644079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
    González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
    J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
    Schaeffer DF; Walsh JC; Kirsch R; Waterman M; Silverberg MS; Riddell RH
    Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and risk factors for primary surgery in 205 patients with Crohn's disease: analysis of a South China cohort.
    Song XM; Gao X; Li MZ; Chen ZH; Chen SC; Hu PJ; He YL; Zhan WH; Chen MH
    Dis Colon Rectum; 2011 Sep; 54(9):1147-54. PubMed ID: 21825896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
    Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.